• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Molecular modeling of the interaction of anthracenyl-amino acid topoisomerase inhibitors with the DNA sequence d(CGTACG).

作者信息

Cummings J, Hadfield J A, Meikle I, McGown A T, Smyth J F

机构信息

Imperial Cancer Research Fund, Medical Oncology Unit, Western General Hospital, Edinburgh, UK.

出版信息

Anticancer Drugs. 1996 Aug;7(6):636-41. doi: 10.1097/00001813-199608000-00003.

DOI:10.1097/00001813-199608000-00003
PMID:8913431
Abstract

Anthracenyl-amino acid and dipeptide conjugates represent new classes of topoisomerase (topo) inhibitors. To investigate the structural basis for their different selectivity against topo I and II and varying potency, the binding of six compounds to d(CGTACG) was studied by molecular modeling. Modeling data were in good agreement with physical data showing that five compounds intercalated DNA with the anthraquinone chromophore orientated in parallel to the long dimension of the d(CpG) base pairs and the amino acid placed in the minor groove. Differences in binding modes emerged which correlated to different biological properties. The amino acid chain of the topo I inhibitor (NU/ICRF 600, gly-phe) extended significantly out from the helical axis horizontal. The amino acid side chains of two topo II inhibitors (NU/ICRF 510, arginine and NU/ ICRF 512, methionine) were inserted into the minor groove, whereas the C-terminal groups (hydrazide) of two potent topo II inhibitors (NU/ICRF 500 and 506, serine) were placed into the minor groove while the amino acid side chains pointed away from the minor groove. These data provide structural information which may prove valuable in rational design of second generation analogs.

摘要

相似文献

1
Molecular modeling of the interaction of anthracenyl-amino acid topoisomerase inhibitors with the DNA sequence d(CGTACG).
Anticancer Drugs. 1996 Aug;7(6):636-41. doi: 10.1097/00001813-199608000-00003.
2
Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates.蒽基氨基酸共轭物对拓扑异构酶I和II的抑制作用的生物化学
Biochem Pharmacol. 1995 Jun 16;49(12):1747-57. doi: 10.1016/0006-2952(95)00086-f.
3
Cytogenetic evaluation of the mechanism of cell death induced by the novel anthracenyl-amino acid topoisomerase II catalytic inhibitor NU/ICRF 500.新型蒽基氨基酸拓扑异构酶II催化抑制剂NU/ICRF 500诱导细胞死亡机制的细胞遗传学评估
Mutat Res. 1995 Aug;344(1-2):55-62. doi: 10.1016/0165-1218(95)90038-1.
4
Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance.
Biochem Pharmacol. 1996 Oct 11;52(7):979-90. doi: 10.1016/0006-2952(96)00301-2.
5
Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505.新型蒽基氨基酸拓扑异构酶I抑制剂NU/ICRF 505对人癌细胞系凋亡的诱导作用
Br J Cancer. 1996 Aug;74(3):374-9. doi: 10.1038/bjc.1996.368.
6
Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography.
Cancer Chemother Pharmacol. 1995;37(1-2):103-9. doi: 10.1007/BF00685636.
7
Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs.
Anticancer Drug Des. 1995 Oct;10(7):515-27.
8
Characterization of the major metabolite of the novel topoisomerase I inhibitor NU/ICRF 505.新型拓扑异构酶I抑制剂NU/ICRF 505主要代谢物的表征
Anticancer Drug Des. 1996 Jul;11(5):367-82.
9
Cell cycle effects of the novel topoisomerase I inhibitor NU/ICRF 505 in a panel of Chinese hamster ovary cell lines.
Eur J Cancer. 1997 Feb;33(2):280-3. doi: 10.1016/s0959-8049(96)00454-6.
10
Molecular interactions of DNA-topoisomerase I and II inhibitor with DNA and topoisomerases and in ternary complexes: binding modes and biological effects for intoplicine derivatives.DNA拓扑异构酶I和II抑制剂与DNA、拓扑异构酶以及三元复合物之间的分子相互作用:英托利辛衍生物的结合模式和生物学效应
Biochemistry. 1994 Aug 2;33(30):9013-23. doi: 10.1021/bi00196a020.